nuclear receptor binding SET domain protein 1Genealiases: ARA267 · KMT3B · SOTOS · SOTOS1 · STO
Q-omics provides the consensus-scored NSD1 profile across patient tissues and cancer cell-line models. NSD1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, NSD1 is differentially expressed in 12, with the highest sampling consensus in LIHC. Additionally, NSD1 RNA expression shows 21,485 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, LIHC, and ACC as cancer lineages where NSD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NSD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NSD1 survival associations across molecular data types. NSD1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NSD1 RNA expression–survival associations across cancer types. High NSD1 expression shows unfavorable associations in ACC, MESO, LGG and LIHC, but favorable associations in KIRC and GBM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for NSD1 RNA expression.
This table summarizes NSD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in LIHC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for NSD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NSD1 shows lower tumor expression in THCA and KICH and higher tumor expression in LIHC, CHOL, LUSC and STAD. The LIHC box plot shows higher NSD1 RNA expression in tumor versus normal tissue (log2 FC = +1.612, t-test p < 0.001).
This table shows molecular features associated with NSD1 in patient tissues and cancer cell lines. In patient samples, NSD1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, NSD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in CNS and LARGE_INTESTINE.
